What is the appropriate dosing of acamprosate for adult patients, and how should renal impairment affect dosing and contraindications?

Acamprosate Dosing and Renal Considerations

The standard dose of acamprosate is 666 mg (two 333 mg tablets) three times daily, but this must be reduced to 333 mg three times daily in moderate renal impairment (CrCl 30-50 mL/min), and the drug is absolutely contraindicated in severe renal impairment (CrCl ≤30 mL/min). 1

Standard Dosing

• Standard adult dose: 666 mg (two 333 mg tablets) three times daily
• Total daily dose: 1998 mg/day
• Dosing may be done without regard to meals, though taking with meals is suggested for patients who regularly eat three meals daily 1
• Treatment should begin as soon as possible after alcohol withdrawal, once abstinence is achieved 1
• Continue treatment even if the patient relapses 1

Critical Renal Dosing Adjustments

Because acamprosate undergoes no hepatic metabolism and is eliminated entirely renally (50% unchanged in urine), renal function is the sole determinant of drug clearance 2, 3:

Moderate Renal Impairment (CrCl 30-50 mL/min)

• Reduce dose to 333 mg three times daily (one tablet per dose)
• This represents a 50% dose reduction 1

Severe Renal Impairment (CrCl ≤30 mL/min)

• Absolute contraindication - do not prescribe 1
• Drug accumulation would be excessive and unpredictable

Normal Renal Function

• No dose adjustment needed
• Pharmacokinetics are time- and dose-independent 3
• Steady-state reached in 5-7 days with accumulation ratio of 2.4 3

Key Clinical Considerations

Hepatic safety advantage: Unlike naltrexone and disulfiram, acamprosate has no hepatic metabolism and no reported hepatotoxicity, making it particularly suitable for patients with alcohol-associated liver disease 2. This is a major advantage since many patients with alcohol use disorder have concurrent liver disease.

Mechanism: Acts as an NMDA receptor antagonist to reduce neuronal hyperexcitability during alcohol withdrawal 2

Efficacy: Number needed to treat to prevent return to any drinking is approximately 12 2

Important Warnings

• Suicidality monitoring: Increased risk of suicidal ideation/attempts compared to placebo (1.4% vs 0.5% in short-term studies; 2.4% vs 0.8% in year-long studies) 1
• Sulfite allergy: Contains sodium sulfite; contraindicated in patients with sulfite hypersensitivity 1
• Must be part of comprehensive psychosocial treatment program - pharmacotherapy alone is insufficient 1

Practical Algorithm for Prescribing

1. Calculate creatinine clearance before initiating therapy
2. If CrCl >50 mL/min: Prescribe 666 mg three times daily
3. If CrCl 30-50 mL/min: Prescribe 333 mg three times daily
4. If CrCl ≤30 mL/min: Do not prescribe; consider alternative (e.g., baclofen, which has been studied in cirrhosis) 2
5. Monitor renal function periodically during treatment, especially in elderly patients or those at risk for declining renal function

Common Pitfalls to Avoid

• Do not assume standard dosing is safe without checking renal function - this is the most critical error, as acamprosate is entirely renally eliminated
• Do not use in dialysis patients - severe renal impairment is an absolute contraindication
• Do not prescribe as monotherapy - must be combined with psychosocial interventions 1
• Do not initiate before detoxification is complete - efficacy has not been demonstrated in patients who haven't achieved abstinence first 1